[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Maplight Therapeutics Inc (MPLT)

Maplight Therapeutics Inc (MPLT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,558,114
  • Shares Outstanding, K 42,618
  • Annual Sales, $ 0 K
  • Annual Income, $ -161,150 K
  • EBIT $ -120 M
  • EBITDA $ -121 M
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.75

Options Overview Details

View History
  • Implied Volatility 221.71% (-160.48%)
  • Historical Volatility 330.80%
  • IV Percentile 43%
  • IV Rank 39.87%
  • IV High 382.63% on 07/23/26
  • IV Low 115.02% on 06/04/26
  • Expected Move (DTE 25) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.24
  • Today's Volume 1,757
  • Volume Avg (30-Day) 490
  • Put/Call OI Ratio 0.59
  • Today's Open Interest 7,726
  • Open Int (30-Day) 4,512
  • Expected Range 12.03 to 12.03

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.37
  • Number of Estimates 5
  • High Estimate $-1.20
  • Low Estimate $-1.44
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.31 +4.24%
on 07/27/26
40.43 -70.84%
on 07/10/26
-21.49 (-64.57%)
since 06/26/26
3-Month
11.31 +4.24%
on 07/27/26
40.43 -70.84%
on 07/10/26
-18.85 (-61.52%)
since 04/27/26

Most Recent Stories

More News
MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MapLight Therapeutics, Inc. (“MapLight”...

MPLT : 11.57 (-68.35%)
Stocks Fall from Early Highs as Chipmakers Retreat

The S&P 500 Index ($SPX ) (SPY ) today is up +0.11%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.54%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.46%. September E-mini S&P futures...

ALK : 46.92 (+1.71%)
SNDK : 1,268.45 (-11.70%)
OXY : 55.69 (-2.81%)
FANG : 199.37 (-2.59%)
STX : 800.03 (-6.07%)
WDC : 487.39 (-6.24%)
AMD : 479.59 (-8.12%)
SPY : 736.32 (-0.35%)
FBRX : 76.42 (+39.50%)
ADSK : 224.30 (+6.94%)
MU : 868.83 (-5.66%)
BKR : 60.78 (+6.17%)
Stocks Rally as Middle East Tensions Ease

The S&P 500 Index ($SPX ) (SPY ) today is up +0.65%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +1.08%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.56%. September E-mini S&P futures...

ALK : 46.92 (+1.71%)
UAL : 119.59 (+1.12%)
INTU : 306.87 (+3.56%)
CVX : 191.70 (-1.59%)
MBLY : 8.02 (-0.37%)
DDOG : 254.85 (+3.24%)
RKLB : 64.92 (+1.58%)
IONQ : 34.89 (+6.24%)
$IUXX : 27,895.15 (-0.83%)
MPLT : 11.57 (-68.35%)
ZNU26 : 108-175 (+0.20%)
MSFT : 391.29 (+2.51%)
MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia

The trial, designed and sized to support registration, met its primary endpoint, with the 210/3 mg BID dose demonstrating a statistically significant improvement in PANSS total score compared to placebo...

MPLT : 11.57 (-68.35%)
MapLight Therapeutics Announces Changes to Board of Directors

SAN FRANCISCO and BOSTON, June 24, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering...

MPLT : 11.57 (-68.35%)
MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder

The IRIS Phase 2 trial did not meet its primary endpoint in social communication deficits associated with ASD A p respecified analysis in adolescents with moderate to severe baseline irritability...

MPLT : 11.57 (-68.35%)
MapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Enrollment completed in ML-007C-MA’s Phase 2 ZEPHYR trial in schizophrenia, with topline results expected by mid-August 2026 Last patient visit completed for ML-004’s Phase 2 IRIS trial in autism...

MPLT : 11.57 (-68.35%)
MapLight Therapeutics to Participate in Upcoming Investor Conferences

SAN FRANCISCO and BOSTON, May 08, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT) today announced that members of its management team will participate in the following investor conferences:...

MPLT : 11.57 (-68.35%)
MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results

Enrollment completed in ML-007C-MA’s ZEPHYR Phase 2 trial in schizophrenia Last patient visit completed for ML-004’s IRIS Phase 2 trial in autism spectrum disorder Topline results from both...

MPLT : 11.57 (-68.35%)
MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected to reach target enrollment (n=300) in April 2026, with topline results expected in the third quarter of 2026 Phase 2 IRIS trial for ML-004...

MPLT : 11.57 (-68.35%)

Business Summary

MapLight Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on improving the lives of patients suffering from debilitating central nervous system disorders. The company's lead product candidate includes ML-007C-MA. MapLight Therapeutics Inc. is based in SAN FRANCISCO.

See More

Key Turning Points

3rd Resistance Point 40.15
2nd Resistance Point 38.56
1st Resistance Point 37.56
Last Price 11.57
1st Support Level 34.97
2nd Support Level 33.38
3rd Support Level 32.38

See More

52-Week High 40.43
Fibonacci 61.8% 29.31
Fibonacci 50% 25.87
Fibonacci 38.2% 22.43
Last Price 11.57
52-Week Low 11.31

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.